MRD assessment with clonoSEQ improves outcomes both for patients and the healthcare system, as patients with undetectable MRD may be able to discontinue active treatment MRD assessment with clonoSEQ improves outcomes both for patients and the healthcare system, as patients with undetectable MRD may be able to discontinue active treatment

View original post here:
Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of clonoSEQ® Assay on Patients with Blood Cancers at the 62nd ASH Annual...